Congenica closed a Series B round (amount undisclosed) in Apr 2017. The company is based in Cambridge, UK. Investors in the round: BGI Genomics (BGI), Future Planet Capital, Healthlink Capital (Healthlink). Data as of 7 Aug 2026.
Amount undisclosed or unconverted.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
